I decided to receive CAR-T cell therapy for multiple myeloma when my previous regimen stopped working and now, I'm living my best life. Following an infection that was resistant to treatment and a few “extra” blood tests, the doctor advised me to see a hematologist (that was OK!) or an oncologist (not so good to hear). In January 2007, the diagnosis of multiple myeloma was followed by several “new normals” for my family and me.

My Decision to Receive CAR-T Cell Therapy for Multiple Myeloma

Caitlin Costello, MD, presents the case of a 60-year-old woman with later relapsed/refractory multiple myeloma and discusses how the treatment landscape has evolved, highlighting remaining unmet needs. Case: A 60-Year-Old Woman with Later Relapsed/Refractory Multiple Myeloma. Clinical Presentation:. A 60-year-old woman who was previously diagnosed 3 years ago with R-ISS...

Patient Profile: A 60-Year-Old Woman with Later Relapsed/Refractory Multiple Myeloma

“Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Patients with newly diagnosed multiple myeloma treated with the four-drug combination of Sarclisa (isatuximab), Kyprolis (carfilzomib), Revlimid (lenalidomide) and dexamethasone (a regimen known as Isa-KRd) experienced what researchers described as “deep and durable” responses, according to study findings.

Isa-KRd Elicits Responses in Some With Newly Diagnosed Multiple Myeloma

COLUMBIA, Mo. — All cancers are difficult to treat, and blood cancers are among the trickiest to handle. However, a common high blood pressure drug is helping to weaken leukemia’s defenses against chemotherapy. Researchers from the University of Missouri School of Medicine are using losartan in a new...

Common high blood pressure drug losartan boosts chemotherapy’s ability to beat leukemia

A healthy 38-year-old who began struggling to finish a half-marathon and experienced night sweats, body aches, and COVID-like symptoms learned he was facing stage 4 non-Hodgkin lymphoma. Despite the shocking diagnosis, he plans to remain positive while he fights the cancer. Lymphoma is a blood cancer, specifically of the immune...

Fit, Healthy Man, 38, With Swollen Knee Felt Covid-Like Symptoms for a Month Before Learning He Had Stage 4 Non-Hodgkin Lymphoma

Bone cancer is a rare type of cancer, which can go undetected for some time before being diagnosed. Although benign (non-cancerous) bone tumors are more common than malignant (cancerous) bone tumors, malignant bone cancer can be an aggressive cancer, and some types grow quickly. Quick progression makes early detection and treatment all the more important.

Bone Cancer Without Knowing: How Long Can It Go Undiagnosed?

Cancer Health

People with type 2 diabetes who used glucagon-like peptide analogs such as Ozempic or Mounjaro had a lower risk for multiple types of cancer compared with those who used insulin, according to study results published in JAMA Network Open. Overweight and obesity have been linked to at least 13 types...

Weight-Loss Drugs May Prevent 10 Types of Cancer

Cleveland, OH

Four months out from the actual surgery, the United States' first robot-assisted dual kidney transplant has been deemed a resounding success. The patient's health and comfort after the procedure lend robot-assisted transplant surgery an extra dose of credibility among those sitting on organ waiting lists. Joanne Kukula, a 70-year-old Ohio...

First Robot-Assisted Dual Kidney Transplant in the US Deemed a Success

The FDA has granted expanded access to TLX101-CDx, a promising PET imaging agent for diagnosing and monitoring glioma. Following the FDA’s agreement to proceed, an expanded access program for TLX101-CDx (Pixclara, 18F-floretyrosine, [18F-FET]), an investigational PET agent used for imaging progressive or recurrent glioma, has been opened.1. Making this...

Expanded Access Opens for TLX101-CDx, Investigational PET Agent in Glioma

Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer. Solange Peters, MD, PhD, full professor, chair, Medical Oncology, Thoracic Malignancies Programme, Department of Oncology, University Hospital of Lausanne, discusses biomarkers that may inform treatment decision-making prior to the administration of immunotherapy in non–small cell lung cancer (NSCLC), as well as which patients may benefit from chemotherapy given with immunotherapy.

Dr Peters on the Use of Biomarkers to Inform Treatment Decision-Making in NSCLC

SurvivorNet

BTK Inhibitor Jaypirca is Now FDA-Approved & May Help Difficult-to-Treat Mantle Cell Lymphoma

The Food and Drug Administration has given the go-ahead for a late-stage clinical trial of an injectable stem cell product that could give new hope to millions of patients suffering from lower back pain caused by degenerative disc disease (DDD). Up to 400 patients with mild to moderate DDD are expected to enroll in the Phase 3 study later this year.

FDA Approves Stem Cell Study for Degenerative Disc Disease

Long-term exposure to proton pump inhibitors and oral anticoagulants was linked to an increased risk of IDA presentation. Long-term exposure to proton pump inhibitors (PPIs) and oral anticoagulants (OACs) was independently associated with the risk of iron deficiency anemia (IDA) development, according to a recent case-control study.1. However, longstanding treatment...

Prescription Medication May Influence Iron Deficiency Anemia Development

Doctors typically divide small cell lung cancer (SCLC) into limited or extensive stages, depending on whether the cancer is in one lung, both lungs, or has spread to distant areas. Staging for small cell lung cancer (SCLC) can help identify how advanced the cancer is and its best treatment. In...

How does small cell lung cancer staging work?

Virginia State

Writers represent independent, third-party users who have joined our contributor program and self-verified their accounts. Writers are expected, like all users, to adhere to our Community Standards.

writer

Cheryl E Preston

Jessica Serfitay flips the script on her previous statement. Virginia soap fans, Soap Opera News reports that Jessica Serfitay (ex Sloan Petersen) on Days of Our Lives posted on social media that her billionaire fiancé had abused her. The actress now says they argued as families do, and she never should have posted anything.

Days of Our Lives alum Jessica Serfitay retracts her statement that her fiance abused her

Pending positive outcomes, Actinium plans to later evaluate Iomab-ACT as a conditioning agent for SCD gene therapies. Actinium’s Iomab-ACT, an investigational antibody radiation conjugate (ARC) intended to serve as an alternative to chemotherapy conditioning agents, has received clearance of an investigational new drug application from the FDA for trial evaluating it as a conditioning agent for patients planning to receive allogeneic bone marrow transplant (allo-BMT) for the treatment of sickle cell disease (SCD).1.

Actinium’s Antibody Radiation Conjugate Iomab-ACT Cleared for US Trial as Conditioning Therapy for SCD Allo-BMT

rolling out

Cervical cancer is a significant health concern for women and others with cervixes worldwide. Early detection and effective treatment are crucial in improving outcomes and survival rates. This article delves into the three most common treatments for cervical cancer, providing detailed information on each to help patients and their loved ones understand their options.

3 most common treatments for cervical cancer

A multicenter, randomized, double-blind, placebo-controlled trial done performed in the the United Kingdom June 2014 to October 2017), enrolled 207 adult patients with symptomatic, radiographic KOA and knee pain (severity ≥4 out of 10) on most days in the past 3 months, after an inadequate response to analgesic medications.

Pain Reduction with Methotrexate in Knee Osteoarthritis

Results suggest cholesterol absorption inhibitors are linked to a lower risk of liver cancer, but no association was observed for other nonstatins like fibrates, omega-3 fatty acids, and niacin. Findings from a recent study are providing clinicians with an overview of the association between nonstatin cholesterol-lowering medications and the risk...

Cholesterol Absorption Inhibitors Linked to Reduced Liver Cancer Risk

Thermo Fisher Scientific announced that it has received an extended 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Optilite Freelite assays for evaluating monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma. MGUS is a lifelong condition characterized by the presence of abnormal...

Thermo Fisher Scientific gets FDA 510(k) clearance for multiple myeloma precursor assays

NewsBreak

The Role of Stem Cell Transplant in R/R Multiple Myeloma

Elo-Pd Follow up and Clinical Workup at Relapse:. BM Biopsy: 65% lambda light chain restricted. M protein 5.2 g/dL; sFLC kappa 5 mg/dL; sFLC lambda 560...

The Role of Stem Cell Transplant in R/R Multiple Myeloma

Comments / 0